Breast cancer incidence and predictions (Monastir, Tunisia: 2002-2030): A registry-based study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
12
2021
accepted:
21
04
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
Breast cancer is a major public health problem worldwide. It is the leading cause of cancer deaths in females. In developing countries like Tunisia, the frequency of this cancer is still growing. The aim of this study was to determine the crude and standardized incidence rates, trends and predictions until 2030 of breast cancer incidence rates in a Tunisian governorate. This is a descriptive study including all female patients diagnosed with breast cancer in Monastir between 2002 and 2013. The data were collected from the cancer register of the center. Tumors were coded according to the 10th version of international classification of disease (ICD-10). Trends and predictions until 2030 were calculated using Poisson linear regression. A total of 1028 cases of female breast cancer were recorded. The median age of patients was 49 years (IQR: 41-59 years) with a minimum of 16 years and a maximum of 93 years. The age-standardized incidence rate (ASR) was of 39.12 per 100000 inhabitants. It increased significantly between 2002 and 2013 with APC of 8.4% (95% CI: 4.9; 11.9). Prediction until 2030 showed that ASR would reach 108.77 (95% CI: 57.13-209.10) per 100000 inhabitants. The incidence and the chronological trends of breast cancer highlighted that this disease is of a serious concern in Tunisia. Strengthening preventive measures is a primary step to restrain its burden.
Identifiants
pubmed: 35617209
doi: 10.1371/journal.pone.0268035
pii: PONE-D-21-39057
pmc: PMC9135193
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268035Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Asian Pac J Cancer Prev. 2015;16(10):4237-45
pubmed: 26028079
J Glob Oncol. 2018 Jul;4:1-16
pubmed: 30085889
Lancet Glob Health. 2020 Aug;8(8):e1027-e1037
pubmed: 32710860
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
BMC Public Health. 2019 Jul 25;19(1):1001
pubmed: 31345204
J Multidiscip Healthc. 2014 Sep 29;7:419-29
pubmed: 25300196
Int J Surg. 2010;8(6):448-52
pubmed: 20601253
EClinicalMedicine. 2021 Jul 07;38:100985
pubmed: 34278281
JAMA. 2002 Jul 17;288(3):321-33
pubmed: 12117397
JAMA Netw Open. 2021 Apr 1;4(4):e214708
pubmed: 33825840
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2015-2020
pubmed: 31350959
Breast J. 2012 May-Jun;18(3):289-91
pubmed: 22487378
Ann Oncol. 2011 Feb;22(2):329-34
pubmed: 20682549
Eur J Cancer. 2014 Jul;50(10):1808-1818
pubmed: 24767469
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S8
pubmed: 21172092
Eur J Cancer. 2017 Sep;83:43-55
pubmed: 28711578
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Cancer Epidemiol. 2018 Aug;55:73-80
pubmed: 29843073
Cancer. 2011 May 15;117(10):2209-18
pubmed: 21523735
Int J Cancer. 2009 Feb 1;124(3):698-712
pubmed: 18988226
Breast Cancer. 2019 Jul;26(4):428-445
pubmed: 30604398
Cancer Causes Control. 2010 Nov;21(11):1777-85
pubmed: 20559704
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
Breast Care (Basel). 2019 Dec;14(6):344-353
pubmed: 31933579
Breast J. 2019 Jul;25(4):795-797
pubmed: 31074067
Lancet. 2008 Aug 23;372(9639):608-10
pubmed: 18722851
Health Informatics J. 2021 Jan-Mar;27(1):1460458220983878
pubmed: 33506703
Sante Publique. 2011 Jan-Feb;23(1):31-40
pubmed: 21786737
Tunis Med. 2009 Jul;87(7):417-25
pubmed: 20063673